» Articles » PMID: 35358511

Mammalian Ddi2 is a Shuttling Factor Containing a Retroviral Protease Domain That Influences Binding of Ubiquitylated Proteins and Proteasomal Degradation

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2022 Mar 31
PMID 35358511
Authors
Affiliations
Soon will be listed here.
Abstract

Although several proteasome subunits have been shown to bind ubiquitin (Ub) chains, many ubiquitylated substrates also associate with 26S proteasomes via "shuttling factors." Unlike the well-studied yeast shuttling factors Rad23 and Dsk2, vertebrate homologs Ddi2 and Ddi1 lack a Ub-associated domain; therefore, it is unclear how they bind Ub. Here, we show that deletion of Ddi2 leads to the accumulation of Ub conjugates with K11/K48 branched chains. We found using affinity copurifications that Ddi2 binds Ub conjugates through its Ub-like domain, which is also required for Ddi2 binding to proteasomes. Furthermore, in cell extracts, adding Ub conjugates increased the amount of Ddi2 associated with proteasomes, and adding Ddi2 increased the binding of Ub conjugates to purified proteasomes. In addition, Ddi2 also contains a retroviral protease domain with undefined cellular roles. We show that blocking the endoprotease activity of Ddi2 either genetically or with the HIV protease inhibitor nelfinavir increased its binding to Ub conjugates but decreased its binding to proteasomes and reduced subsequent protein degradation by proteasomes leading to further accumulation of Ub conjugates. Finally, nelfinavir treatment required Ddi2 to induce the unfolded protein response. Thus, Ddi2 appears to function as a shuttling factor in endoplasmic reticulum-associated protein degradation and delivers K11/K48-ubiquitylated proteins to the proteasome. We conclude that the protease activity of Ddi2 influences this shuttling factor activity, promotes protein turnover, and helps prevent endoplasmic reticulum stress, which may explain nelfinavir's ability to enhance cell killing by proteasome inhibitors.

Citing Articles

Activators of the 26S proteasome when protein degradation increases.

Lee D Exp Mol Med. 2025; 57(1):41-49.

PMID: 39779978 PMC: 11799193. DOI: 10.1038/s12276-024-01385-x.


DDI2 protease controls embryonic development and inflammation via TCF11/NRF1.

Nedomova M, Haberecht-Muller S, Moller S, Venz S, Prochazkova M, Prochazka J iScience. 2024; 27(10):110893.

PMID: 39328932 PMC: 11424978. DOI: 10.1016/j.isci.2024.110893.


Early recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2.

Ibtisam I, Kisselev A Elife. 2024; 12.

PMID: 38619391 PMC: 11018354. DOI: 10.7554/eLife.91678.


Cell-type-specific gene expression and regulation in the cerebral cortex and kidney of atypical Setbp1 Schinzel Giedion Syndrome mice.

Whitlock J, Soelter T, Howton T, Wilk E, Oza V, Lasseigne B J Cell Mol Med. 2023; 27(22):3565-3577.

PMID: 37872881 PMC: 10660642. DOI: 10.1111/jcmm.18001.


ER-trafficking triggers NRF1 ubiquitination to promote its proteolytic activation.

Chavarria C, Zaffalon L, Ribeiro S, Op M, Quadroni M, Iatrou M iScience. 2023; 26(10):107777.

PMID: 37720101 PMC: 10502413. DOI: 10.1016/j.isci.2023.107777.


References
1.
Leto D, Morgens D, Zhang L, Walczak C, Elias J, Bassik M . Genome-wide CRISPR Analysis Identifies Substrate-Specific Conjugation Modules in ER-Associated Degradation. Mol Cell. 2018; 73(2):377-389.e11. PMC: 6338494. DOI: 10.1016/j.molcel.2018.11.015. View

2.
Gomez T, Kolawa N, Gee M, Sweredoski M, Deshaies R . Identification of a functional docking site in the Rpn1 LRR domain for the UBA-UBL domain protein Ddi1. BMC Biol. 2011; 9:33. PMC: 3126750. DOI: 10.1186/1741-7007-9-33. View

3.
Siva M, Svoboda M, Veverka V, Trempe J, Hofmann K, Kozisek M . Human DNA-Damage-Inducible 2 Protein Is Structurally and Functionally Distinct from Its Yeast Ortholog. Sci Rep. 2016; 6:30443. PMC: 4962041. DOI: 10.1038/srep30443. View

4.
Motosugi R, Murata S . Dynamic Regulation of Proteasome Expression. Front Mol Biosci. 2019; 6:30. PMC: 6504791. DOI: 10.3389/fmolb.2019.00030. View

5.
Koltai T . Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. F1000Res. 2015; 4:9. PMC: 4457118. DOI: 10.12688/f1000research.5827.2. View